After Two-Year Delay, J&J Plans To Start Trial Ottava Surgical Robot In 2024
J&J originally projected its Ottava soft-tissue robotic surgery system would enter first-in-human trials in 2022 and reach the market by 2023, but the development has been delayed by technical challenges and COVID-19-related disruptions. Now the company plans to start trials of a four-armed version of the device in about a year.
You may also be interested in...
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with Abbott’s head of Lingo Biowearables and top executives at Twin Health. Reed Miller provides an update on J&J MedTech’s launch of the Ottava soft-tissue robotic surgery system and Barnaby Pickering talks about his recent interview with Leo Grady, former CEO of Paige AI, to talk about his new start-up Jona.
News We’re Watching: AHA Meeting In Philly; Surgeons Call For TAVR Caution; China Approves J&J's Monarch Robot
New clinical trial data presented at the American Heart Association Scientific Sessions in Philadelphia dominated the R&D news this week. Here are some of the highlights from the conference as well as some other bits of medtech industry news you may have missed.
One doctor is using his expertise to advocate for better premarket surveillance of cancer-treatment devices.